Phase 1 Oncology Clinical Trials

6 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–6 of 6 trials

Recruiting

Phase 1

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

OncologyMEK MutationRAF Gene Mutation

Nested Therapeutics, Inc230 enrolled23 locationsNCT06326411

Recruiting

Phase 1

A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies

OncologyMalignant Solid Tumor

GE Healthcare50 enrolled2 locationsNCT05629689

Recruiting

Phase 1

Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

Solid Tumor, AdultOncology

Trethera94 enrolled2 locationsNCT05055609

Recruiting

Phase 1Phase 2

A Study in Patients With Advanced Cancers

Advanced Solid TumorCancerAdvanced Cancer+1 more

BiOneCure Therapeutics Inc.332 enrolled3 locationsNCT05320588

Completed

Phase 1

A Phase 1 Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of the AUM001 in Healthy Volunteers

Oncology; This is a healthy volunteer study. It is proposed that the drug will be evaluated for the treatment of patients with a range of solid and liquid tumours in Phase II.

AUM Biosciences Pty Ltd24 enrolled1 locationACTRN12620000572965

Not Yet Recruiting

Phase 1

A trial examining the bioavailability of 4 doses of 3 different formulations of Afuresertib - a Gelatin Formulation and Two Prototype Formulations of Afuresertib, in Normal Healthy Volunteers in both the fasted and non-fasted states .

Oncology (general Cancer). Previous research with this agent has been conducted in Multiple Myeloma. Hodgkins Disease, non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Langerhans Cell Histiocytosis

GlaxoSmithKline36 enrolled1 locationACTRN12613000409774